Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system

Neurobiol Dis. 2021 Mar:150:105259. doi: 10.1016/j.nbd.2021.105259. Epub 2021 Jan 9.

Abstract

Neuronal regeneration in the injured central nervous system is hampered by multiple extracellular proteins. These proteins exert their inhibitory action through interactions with receptors that are located in cholesterol rich compartments of the membrane termed lipid rafts. Here we show that cholesterol-synthesis inhibition prevents the association of the Neogenin receptor with lipid rafts. Furthermore, we show that cholesterol-synthesis inhibition enhances axonal growth both on inhibitory -myelin and -RGMa substrates. Following optic nerve injury, lowering cholesterol synthesis with both drugs and siRNA-strategies allows for robust axonal regeneration and promotes neuronal survival. Cholesterol inhibition also enhanced photoreceptor survival in a model of Retinitis Pigmentosa. Our data reveal that Lovastatin leads to several opposing effects on regenerating axons: cholesterol synthesis inhibition promotes regeneration whereas altered prenylation impairs regeneration. We also show that the lactone prodrug form of lovastatin has differing effects on regeneration when compared to the ring-open hydroxy-acid form. Thus the association of cell surface receptors with lipid rafts contributes to axonal regeneration inhibition, and blocking cholesterol synthesis provides a potential therapeutic approach to promote neuronal regeneration and survival in the diseased Central Nervous System. SIGNIFICANCE STATEMENT: Statins have been intensively used to treat high levels of cholesterol in humans. However, the effect of cholesterol inhibition in both the healthy and the diseased brain remains controversial. In particular, it is unclear whether cholesterol inhibition with statins can promote regeneration and survival following injuries. Here we show that late stage cholesterol inhibition promotes robust axonal regeneration following optic nerve injury. We identified distinct mechanisms of action for activated vs non-activated Lovastatin that may account for discrepancies found in the literature. We show that late stage cholesterol synthesis inhibition alters Neogenin association with lipid rafts, thereby i) neutralizing the inhibitory function of its ligand and ii) offering a novel opportunity to promote CNS regeneration and survival following injuries.

Keywords: Axonal regeneration; Cholesterol inhibition; Neuronal survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology
  • Axons / drug effects
  • Axons / pathology
  • Cell Survival
  • Chick Embryo
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lovastatin / pharmacology*
  • Membrane Microdomains / drug effects
  • Membrane Microdomains / metabolism
  • Membrane Proteins / drug effects
  • Membrane Proteins / metabolism
  • Myelin Sheath
  • Nerve Regeneration / drug effects*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Optic Nerve / drug effects*
  • Optic Nerve / metabolism
  • Optic Nerve / pathology
  • Optic Nerve Injuries / metabolism
  • Optic Nerve Injuries / pathology
  • Photoreceptor Cells
  • Prenylation
  • Prodrugs
  • Rats
  • Retina
  • Retinitis Pigmentosa
  • trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride / pharmacology

Substances

  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Membrane Proteins
  • Prodrugs
  • neogenin
  • trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride
  • Lovastatin

Grants and funding